BridgeMD
New treatment option for Herpes Zoster
Official title Electroacupuncture Regulation of Immune Cells in Herpes Zoster
ClinicalTrials.gov ID: NCT06643247
What this study is testing
What is Drug?
Drug is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for herpes zoster.
Also referred to as Medication.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Herpes Zoster (HZ), caused by the Varicella-Zoster Virus (VZV), is a common infection characterized by localized pain and blistering, with higher incidence in females. HZ affects patients' physical health, mental well-being, and quality of life.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 70, women only. Healthy volunteers may be eligible.
You may be able to join if
- for HZ:
- Meets HZ diagnostic criteria;
- Female, aged between 50 and 70 years;
- Disease duration ≤7 days, with no prior antiviral, analgesic, or other treatments;
- Herpetic lesions limited to the trunk, within 1 to 3 dermatomes;
You likely can't join if
- Special types of herpes zoster, including ophthalmic, otic, visceral, meningeal herpes zoster, and zoster sine herpete;
- Women who are planning to conceive, pregnant, or breastfeeding;
- Patients with severe primary diseases of the circulatory, respiratory, or endocrine systems, or systemic failure;
- Patients with bleeding tendencies;
- Use of corticosteroids or immunosuppressants within the past month.
See the full eligibility criteria
- for HZ:
- Meets HZ diagnostic criteria;
- Female, aged between 50 and 70 years;
- Disease duration ≤7 days, with no prior antiviral, analgesic, or other treatments;
- Herpetic lesions limited to the trunk, within 1 to 3 dermatomes;
- Willing to participate in the trial and has signed the informed consent form. for HC:
- No history of HZ or major cardiovascular, respiratory, digestive, urinary, hematologic, endocrine, or neurological diseases;
- Age-matched female HC volunteers for the HZ group;
- Clear consciousness and ability to communicate normally;
- Fully understands the study protocol, demonstrates good compliance, and is willing to cooperate with the study;
- Has signed a written informed consent form.
- Special types of herpes zoster, including ophthalmic, otic, visceral, meningeal herpes zoster, and zoster sine herpete;
- Women who are planning to conceive, pregnant, or breastfeeding;
- Patients with severe primary diseases of the circulatory, respiratory, or endocrine systems, or systemic failure;
- Patients with bleeding tendencies;
- Use of corticosteroids or immunosuppressants within the past month.
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 50 years to 70 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.